Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2015

View Archived Issues

Merck & Co. describes discovery of novel DGAT2 inhibitors

Discovery and optimization of novel HIV integrase inhibitors from BMS

DelMar Pharmaceuticals receives additional funding to develop VAL-083

Novartis gives details on early testing of potent BCR-ABL allosteric inhibitor

Omeros reports additional data from phase II trial of OMS-721

Novel SYK inhibitor shows antitumor activity in preclinical models

FDA accepts filing of supplemental BLA for Keytruda

New translocator protein ligands target mitochondrial dysfunction in Alzheimer's disease

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

TUBE Pharmaceuticals discloses cytotoxic compounds for cancer

Roche develops PDE10A inhibitors

FDA approves first treatment for hypoactive sexual desire disorder in women

Enanta Pharmaceuticals designs anti-HCV agents

Remedy Pharmaceuticals starts pilot trial of Cirara for spinal cord injury

Theravance Biopharma patent discloses NEP inhibitors

Biohaven acquires ALS Biopharma glutamate signaling modulator portfolio

FDA awards QIDP status to Matinas BioPharma's encochleated amphotericin B

Kadimastem's astrocyte therapy increases survival in animal model of ALS

Lilly launches Humalog U-200 KwikPen in U.S.

Intarcia reports results from ITCA-650 phase III trial FREEDOM-2

NantKwest starts phase II trial of NK-92 in Merkel cell carcinoma

Peptide drug developer Phoundry Pharmaceuticals completes financing

Phase II study examines combination of pembrolizumab and IL-12 gene therapy in melanoma

Biogen announces ALS genomics collaboration

Bavarian Nordic initiates first-in-human study of RSV vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...